focu remain adu file
accept like launch
delay pt
expect covid impact spinraza tysabri clinic
sale fell con management provid color impact
near-term focu earn call aducanumab file
on-going type meet fda keep us confid potenti fda file
accept like file submiss origin file timelin
earli despit neg impact busi expect
area minim impact aducanumab file complet
pre-bla meet summer expect signific tecfidera
mail-ord biosimilar busi expect increas
report revenu con lower
expect ms spinraza sale respect
howev tysabri spinraza could see neg impact
could reflect guidanc updat earn
call tecfidera report con interferon
con tysabri report vs con spinraza sale
in-lin strh estim short consensu
although tecfidera benefit due know
long off-set declin interferon tysabri given need
infus hospit management highlight work at-hom
infus tysabri see delay new patient start spinraza
regimen complianc guidanc remain
revenu sale sg sale
tax non-gaap ep howev expect
guidanc chang earn updat call
on-going interact fda keep us confid level
interest despit file timelin push earli file
order priorit qualiti submiss aducanumab
highlight data complet patient multipl biomark
endpoint biib open bla start submit modul
file sever interact fda use mechan
type meet sinc last june prepar pre-
tr target
bla meet summer complet bla file start discuss eu
japan file aducanumab
addit commentari aducanumab call
said big chang new question fda type meet sinc
continu conduct subgroup analys bla
sever modul relat manufactur process nonclin section clinic overview
say nonclin section alreadi place sinc earli day
dian-tu studi confirm belief high dose need robust remov amyloid plaqu
see clinic benefit
aducanumab could administ at-hom infus common practic
requir file initi embark studi collect addit data re-dos
patient previous enrol aducanumab studi infus everi wk
expect adequ suppli meet anticip demand aducanumab expect
suppli initi north carolina facil larger commerci suppli switzerland
facil expect oper suppli
recal emerg posit studi primari secondari endpoint engag
differ result due trial amend dose accord
could see neg impact new patient start complianc
spinraza tysabri neg impact clinic trial spinraza
neg impact new patient start complianc dose regimen environ
tysabri infus give physician offic work toward home infus
tysabri clinic trial paus enrol molecul may suppress immun system
other on-going patient safeti data integr remain intact
spinraza sale devot studi higher dose underway howev
see uncertainti around new patient start complianc due near-
term note could decreas new patient start decreas complianc due
us ex-u expect continu physician hospit
priorit patient work ensur access spinraza patient phase
devot studi underway evalu whether higher dose spinraza could potenti greater
efficaci teen adult sma base recent pk/pd data suggest individu higher
csf concentr spinraza achiev greater improv chop-intend score motor
tecfidera/vumer show strength could expect ms uncertainti
declin tysabri due interferon howev im plegridi could
improv toler complianc approv regulatori file im plegridi us/eu
file follow bioequival studi show im may reduc inject site reaction vs sc dose
covid impact clinic trial put paus studi suppress immun system
expect major remain mid-to-l stage readout occur end aim
continu on-going trial long possibl priorit patient safeti data integr
allow on-going trial enrol new patient may stop case case basi
paus initi new trial evalu molecul suppress immun system
modul antivir respons come month includ plan phase pegyl
ligand fab sle collabor ucb
anticip delay data readout includ phase studi iv glibenclamid
larg hemospher infarct due administr drug acut hospit set
mitig impact studi reduc miss site visit studi withdraw
implement strategi includ remot monitor data verif support patient
page
staff travel studi site launch direct deliveri servic patient investig therapi
support at-hom infus telemedicin option
net cfo cash debt financi flexibl
capac bd includ collabor up-front
licens fee milestones/royalti recent announc collabor
agreement sangamo nr develop gene therapi ad pd neuromuscular diseas
neurolog diseas zinc finger protein technolog deliv via aav
stock addit licens fee mileston
tier high singl digit sub-teen double-digit royalti
model updat maintain buy pt goe prior adjust model
reflect financi result adjust base management color due impact
busi
catalyst fda accept aducanumab bla file complet
regulatori decis im formul plegridi us/eu ms
page
figur million dollar except per share data
strh research compani report updat
page
incom statement biogen sale lingo sale product revenu revenu intang non- profit oper expens itemsnet interest incom pre-tax incom provis attrib non-control net ep per base growthamort acquir non recur net incom ep per share outstand share outstand biogen inc
figur million dollar except per share data
strh research compani report updat
page
balanc sheet collater loan current total current asset market non current total asset liabil sharehold tax payables- accru current portion note total current liabil note long term defer tax lt total liabil addit paid retain total sharehold total liabil sharehold biogen inc
figur million dollar except per share data
strh research compani report updat
page
statement operationsnet non-oper itemsdepreci current accru current excl note oper investingproce sale manufactur sale matur market market consider invest financingdebt financ ce ce market secur biogen inc
figur million dollar except per share data
strh research compani report updat
page
base work payment free cash present valu growth termin tv outstand compani report strh free inc
inc biopharmaceut compani engag discov develop deliv
therapi neurolog neurodegen diseas offer tecfidera avonex plegridi
tysarbi zinbryta fampyra treatment multipl sclerosi spinraza treatment
spinal muscular atrophi fumaderm treatment sever plaqu psoriasi compani
found charl weissmann heinz schaller kenneth murray walter gilbert phillip allen
sharp headquart cambridg
surpris announc fda aducanumab phase data thesi hing
aducanumab obtain fda approv pipelin tauopathi al part
earli give credit pipelin ad wait data biogen
grow biosimilar pipelin expans china market samsung bioepi
collabor think street underappreci abil grow anoth segment beyond ms
spinraza sma rate buy pt
valuat risk
price target deriv dcf assum ms sale declin
spinraza peak sale adjust ad sale model
dcf termin growth rate discount rate instead matur
biotech compani account potenti commerci execut ad termin valu
arriv pt
risk rate price target includ on-going fda reject aducanumab bla file ad
competit sma pipelin visibl
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
